IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology
Brain · 2026
DOI: 10.1093/brain/awaf410 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2026. Verfasst von Gianvito Masi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Yale School of Medicine, New Haven, CT 06511, USA. Hauptthemen laut MEDLINE: Receptors, Cholinergic, Myasthenia Gravis, Autoantibodies, Receptor Protein-Tyrosine Kinases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Rare Diseases Clinical Research Consortia of the NIH and MGNet, Myasthenia Gravis Foundation of America, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Patients with muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG) develop muscle weakness due to functionally monovalent immunoglobulin (Ig) G4 autoantibodies (Abs) that target MuSK and disrupt acetylcholine receptor (AChR) clustering. Emerging evidence from other autoimmune conditions suggests that Abs of the IgA class—the archetypal immunoglobulin isotype at mucosal sites—may synergize with IgG Abs, contributing to pathology. In MuSK MG, however, the presence of disease-specific IgA Abs has not yet been recognized, limiting a broader understanding of IgG4-driven autoimmunity. To address this knowledge gap, we leveraged cell-based binding assays, patient-derived recombinant monoclonal autoantibodies (mAbs), high-throughput B-cell receptor sequencing, C2C12 mouse myotube cultures and passive immunization experiments. Among 112 sera collected from 25 patients with MuSK MG (discovery cohort), MuSK-specific IgA Abs were detected in eight samples, corresponding to 3/25 (12%) patients. This finding was validated in a second, independent cohort (validation cohort; n = 14 individuals), wherein one additional patient (1/14; 7.1%) harboured MuSK IgA Abs. Across all cases, MuSK IgA Abs coexisted with MuSK IgG Abs, while domain mapping demonstrated a polyclonal IgA response in 2/4 (50%) patients. Notably, in a paradigmatic case with longitudinal samples spanning over a decade, MuSK IgA seropositivity was persistent, and clonally expanded MuSK IgA B cells showed remarkable resistance to therapeutic B-cell depletion. We generated three patient-derived MuSK-specific IgA mAbs for in-depth molecular profiling. These mAbs were highly hypermutated, bound to distinct MuSK domains and shared target epitopes with MuSK IgG4 mAbs. Two IgA mAbs cross-reacted with murine MuSK, enabling functional studies with C2C12 myotubes. Mechanistically, individual IgA mAbs promoted AChR clustering (indicative of MuSK agonism) and partially antagonized the pathogenic effects of MuSK IgG4 monovalency. When modelling a polyclonal response, however, the combination of the same IgA mAbs significantly impaired cluster formation, demonstrating cooperative pathogenic potential. Consistent with this, passive transfer of both IgA clones into mice induced a myasthenic phenotype characterized by progressive weight loss, muscle weakness and structural disruption of the neuromuscular junction (effects similar to those elicited by a functionally monovalent MuSK IgG4 mAb). These findings uncover a previously unrecognized pathogenic Ab isotype in a subset of patients with MuSK MG and show a mechanism through which bivalent MuSK Abs may synergize to induce pathology. The identification of MuSK-specific IgA B cells could signal a role of mucosal or environmental factors in the pathogenesis of MuSK MG and other IgG4-mediated diseases, offering a worthy avenue for future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Yale School of Medicine, New Haven, CT 06511, USA.
- Department of Immunobiology, Yale School of Medicine, New Haven, CT 06510, USA.
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 41008, China.
- Yale College, New Haven, CT 06511, USA.
- Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome 00168, Italy.
- Università Cattolica del Sacro Cuore, Italy.
ORCID-Profile: Gianvito Masi, Akiko Iwasaki, Richard J Nowak, Kevin C O'Connor
Förderung
- Rare Diseases Clinical Research Consortia of the NIH and MGNet
- Myasthenia Gravis Foundation of America
- National Institute of Allergy and Infectious Diseases
- Muscular Dystrophy Association
- NIAID NIH HHS
- NIH HHS
- Rare Diseases Clinical Research Network
- NINDS NIH HHS
Zitieren
APA
Masi, G., Chen, K., Bayer, A. C., Bayarri-Olmos, R., Pham, M. C., Wallace, A., Falso, S., Evoli, A., Iorio, R., Hoehn, K. B., Iwasaki, A., Nowak, R. J., & O'Connor, K. C. (2026). IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology. Brain. https://doi.org/10.1093/brain/awaf410
Vancouver
Masi G, Chen K, Bayer AC, Bayarri-Olmos R, Pham MC, Wallace A, et al. IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology. Brain. 2026. doi:10.1093/brain/awaf410
BibTeX
@article{Masi2026,
author = {Masi, Gianvito and Chen, Kangzhi and Bayer, Alexandra C and Bayarri-Olmos, Rafael and Pham, Minh C and Wallace, Annabel and Falso, Silvia and Evoli, Amelia and Iorio, Raffaele and Hoehn, Kenneth B and Iwasaki, Akiko and Nowak, Richard J and O'Connor, Kevin C},
title = {IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology},
journal = {Brain},
year = {2026},
doi = {10.1093/brain/awaf410}
}
EUVIMED